Navigation Links
AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research
Date:6/16/2009

Washington, DC June 12, 2009 -- The Association for Molecular Pathology (AMP) today released the text of a comment letter it has provided to the Federal Coordinating Council for Comparative Effectiveness Research (CER) in which AMP sets forth its recommendations for priority areas on which to focus CER activities.

"CER is garnering substantial attention in Congress and among other policy makers who see it as a method to examine the comparative effectiveness of treatments, including how they relate to coverage and reimbursement decisions" wrote AMP President Jan A. Nowak, MD, Ph.D. "Diagnostic tests will most definitely be included in this paradigm, especially when the effectiveness of treatments will vary among different population subgroups. Unfortunately, the value of diagnostics in improving clinical outcomes has not been appreciated adequately in the past; therefore, considering the role of genomics under CER will be critical."

Dr. Nowak continued to say that in order for CER to be a success, it will be essential to train experts in diagnostics (including molecular diagnostics) in current health services research methods as well as to train health services researchers in the technical areas they will assess. This cross training will be essential to ensure that the research methods are technology appropriate.

"There is much less experience in assessing the role of the diagnostic test itself in appropriate and cost effective management of individual patients," wrote Dr. Nowak. "Therefore, AMP encourages the Coordinating Council to invest in the cross-training of researchers and diagnostics experts as well as to build the infrastructure within the agencies to understand and review data from different types of technologies."

The AMP letter recommends the devepment of a model process for CER regarding clinical laboratory tests. This model should include the creation of a panel of experts consisting of physicians and scientists, including laboratorians with molecular diagnostics expertise, economists, and reimbursement specialists; the creation of an electronic clearinghouse for information on CER projects similar to www.clinicaltrials.gov; the development and adoption of standards for the collection and storage of data from genetic testing laboratories in order to facilitate interoperability among databases; and a requirement that data from technologies and tests being assessed be generated from CLIA-, CAP-, ISO-, or FDA- certified institutions.

Additionally, AMP wrote that in order to routinely incorporate information that relates patient outcomes to genetic variations into clinical care, there is a need to jointly fund large, carefully designed comparative effectiveness trials for molecular tests with observational comparative effectiveness studies that complement the randomized controlled trials by including patients who do not necessarily meet the inclusion criteria for traditional prospective trials.

AMP's comment letter also called for measures for the evaluation of genomic tests and clinical molecular diagnostics laboratories. For the public to reap the benefits of effective molecular tests, it is critical that all laboratories meet high performance standards and participate in proficiency testing programs utilizing appropriate reference and control materials. Specifically the letter recommends funding a program to develop new reference materials to aid the continued advancement of quality measures in laboratory medicine; the development of proficiency testing methods as alternatives to distributing surrogate test specimens; and, the development of appropriate quality assurance measures for new technologies such as whole genome sequencing.

Finally, as Dr. Nowak wrote, "Despite the possibility of saving the healthcare system thousands of dollars per patient and improving the quality of care, diagnostics have been historically under valued. AMP hopes that any CER activities will include research to explore the value, beyond simply cost, of diagnostic tests to patients, providers, payers and the larger health care system."


'/>"/>

Contact: Mary Steele Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Related medicine news :

1. Brain Injury Association of America Urges President Obama to Include Cognitive Rehabilitation for Returning Service Members as a Part of TRICARE Coverage
2. Founder of Snoring Isn't Sexy, LLC Urges All Dentists to Screen Their Patients for Snoring and Obstructive Sleep Apnea
3. MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage
4. FDA Report Urges Tougher Acetaminophen Warning
5. MyOutcomes Urges Government Leaders to Employ Consumer-Driven Outcomes Management in Reforming Behavioral Health System
6. Planned Parenthood Urges Gov. Schwarzenegger to Rescind Harmful Budget Cuts to Womens Health Care
7. Americans United for Life Memo Urges Senators to Consider New Abortion Polling Data Showing Majorities of all Parties Oppose Judicial Activism, Support Abortion Regulations
8. Disability Activist Urges Obama to Escalate Stem Cell Research to End Paralysis For Millions of Americans
9. With Obesity Key Driver of Rising Health Care Costs, National Business Group on Health Urges Tax Code Changes
10. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
11. Red Cross Urges Families and Communities to Prepare During Swine Flu Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Diego, CA (PRWEB) , ... December 05, 2016 , ... ... seen and heard the dangers and downsides of patients who do not do their ... The field of cosmetic dermatology is in the midst of a renaissance and every ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
(Date:12/5/2016)... WOONSOCKET, R.I. , Dec. 5, 2016 /PRNewswire/ ... CVS ) Research Institute and the U.S. ... the Assistant Secretary for Preparedness and Response (ASPR), ... showed that automated pharmacy notifications encourage patients ... a forecasted natural disaster. The study also affirms ...
Breaking Medicine Technology: